Volatile day for CAR-T biotechs after FDA announces cancer safety review
“We also believe the news has no read-through to companies that use nonviral approaches for CAR insertion, such as Poseida, and minimal impact on companies developing allogeneic approaches.” William Blair wrote. Allogeneic companies include Allogene, CRISPR Therapeutics, Nkarta, Century Therapeutics and Poseida Therapeutics. The firm said that “the host immune system more readily and rapidly rejects these compared to autologous approaches.”
Allogeneic cell therapies use stem cells from a donor that matches the patients to treat cancers such as leukemia, lymphoma and multiple myeloma. Autologous cell therapy uses a patient’s own cells that are removed, tweaked with the medicine and then reinfused back into the body.
Volatile day for CAR-T biotechs after FDA announces cancer...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |